|
業務類別
|
Biotechnology |
|
業務概覽
|
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment. |
| 公司地址
| 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010 |
| 電話號碼
| +1 212 994-8250 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.minktherapeutics.com |
| 員工數量
| 15 |
| Dr. Jennifer S. Buell, PhD |
President, Chief Executive Officer and Director |
美元 448.00K |
30/04/2026 |
| Mr. Austin Charette |
Principal Accounting Officer |
-- |
19/03/2026 |
| Ms. Melissa Orilall |
Principal Financial Officer |
-- |
19/03/2026 |
|
|
| Mr. Ulf Wiinberg |
Independent Director |
30/04/2026 |
| Dr. Garo H. Armen, PhD |
Chairman of the Board |
30/04/2026 |
| Mr. Brian J. Corvese |
Independent Director |
30/04/2026 |
| Dr. Jennifer S. Buell, PhD |
President, Chief Executive Officer and Director |
30/04/2026 |
| Ms. Barbara Ryan |
Independent Director |
30/04/2026 |
| Mr. Peter Behner |
Independent Director |
30/04/2026 |
| Dr. John Holcomb, M.D. |
Independent Director |
30/04/2026 |
|
|
|
|
